Traces Thursday explores why clopidogrel works for some patients and not others

Stand Up for Science has published the seventh installment of its “Traces Thursday” series, this time focused on clopidogrel and the genetic reasons some patients do not respond to the blood thinner. The story highlights how pharmacogenomics is reshaping drug development and why research must continue after a medicine reaches the market.

Why it matters: - Clopidogrel’s mixed results in different patients show why the same drug can work well for one person and fail for another. - The case underscores a broader shift in medicine toward pharmacogenomics, or using genetic differences to explain drug response and dosing. - The story also argues that drug development does not end at FDA approval, because real-world use can expose limits that were not visible in early testing.

What happened: - Stand Up for Science released the seventh installment of its weekly “Traces Thursday” series yesterday. - This week’s story, “Blood thinners and pharmacogenomics,” examines the history of clopidogrel, sold commercially as Plavix. - The FDA approved clopidogrel in 1997. - The series traces how researchers developed clopidogrel as a stronger blood thinner with fewer side effects than aspirin. - Stand Up for Science said the series will continue every Thursday on the Science Fight Club Substack.

The details: - Clopidogrel is a pro-drug, meaning the pill contains an inactive precursor that the body must convert into the active compound. - A specific liver enzyme converts clopidogrel into its active form. - Genetic variation affects the enzymes that metabolize the drug because human populations differ through evolutionary and geographic history. - In a more diverse patient population, clopidogrel proved ineffective for some patients whose genetics prevented adequate metabolism of the pro-drug. - Aspirin, covered in last week’s Traces Thursday story, can help prevent blood clotting and reduce cardiovascular events such as heart attacks. - Aspirin also carries side effects including stomach irritation and bleeding. - The lesson from clopidogrel is that doctors and researchers need to understand both how a medicine works in general and how individual genetics and other variables affect response.

Between the lines: - The series is making an argument about scientific process, not just one drug: foundational research often takes decades before producing visible medical benefits. - The clopidogrel example shows how a breakthrough can create a second challenge, which is figuring out who benefits and who does not. - Dr. Jeremy Berg said more than 100 drugs are known to be affected by genetic variations that alter efficacy. - Berg said the field of pharmacogenetics is still in its early stages. - The broader message is aimed at current debates over federal science funding, with the series framing basic and biomedical research as a long-term investment.

What’s next: - Stand Up for Science plans to publish the remaining installments of the twelve-part series each Thursday. - Berg is available for comment. - The organization says the series will continue to appear on the Science Fight Club Substack.

The bottom line: - Clopidogrel is a reminder that the best drug on paper may not work the same way for every patient, and genetics can be the difference between success and failure.